文献速递泌尿系结石

单剂量围手术期普瑞巴林在输尿管镜术中的随机对照试验

Randomized Controlled Trial of Single-dose Perioperative Pregabalin in Ureteroscopy.
PubMed 文献 · J Urol · 2023-06-12

这项在单一机构开展的注册、盲法、安慰剂对照试验纳入118例接受输尿管镜术的患者,术前1小时给予300 mg普瑞巴林或安慰剂。结果显示,普瑞巴林组术后疼痛评分高于安慰剂组(3.7 vs 2.0,P = .004),在认知测量或不良事件报告方面无差异。结论认为,与安慰剂相比,普瑞巴林未减轻术后疼痛。

要点

  • 普瑞巴林组术后疼痛评分高于安慰剂组(3.7 vs 2.0,P = .004)。
  • 在认知测量或不良事件报告方面,两组无差异。
  • 作者认为,泌尿外科医生不应在输尿管镜术中常规使用该辅助药物。

核心结论

  • 与安慰剂相比,单剂量围手术期普瑞巴林未减轻输尿管镜术后的疼痛。
  • 作者认为,泌尿外科医生不应在输尿管镜术中常规使用该辅助药物,因为它不太可能提供益处。

研究设计与样本

  • 这是一项经机构审查委员会批准并注册的盲法、安慰剂对照试验,在单一机构开展。
  • 共纳入118例接受输尿管镜术且病史不限制使用阿片类药物、加巴喷丁类药物和非甾体药物的患者。
  • 患者在输尿管镜术前1小时接受300 mg普瑞巴林或安慰剂。
  • 在给药前和术后1小时使用视觉模拟量表评估疼痛,并在术后前30天评估临床因素、疼痛评分、认知替代指标、患者满意度和阿片类药物处方。

主要发现

  • 在2年期间共纳入118例患者。
  • 接受普瑞巴林的患者比接受安慰剂的患者年轻(中位数44岁 vs 57岁)。
  • 接受普瑞巴林的患者术后疼痛评分更高(3.7 vs 2.0,P = .004),在考虑患者年龄和术前疼痛评分后,该发现仍具有统计学显著性。
  • 在认知测量或不良事件报告方面无差异。

临床怎么用

  • 作者认为,泌尿外科医生不应在输尿管镜术中常规使用该辅助药物,因为它不太可能提供益处。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ureteroscopy is a commonly performed procedure, with postoperative pain that can lead to revisits and opioid prescribing. Perioperative gabapentinoids have shown promise in decreasing pain and opioid use. We hypothesized that single-dose perioperative pregabalin would be safe and efficacious for decreasing pain after ureteroscopy. MATERIALS AND METHODS: This was an Institutional Review Board-approved and registered blinded, placebo-controlled trial conducted at a single institution. Patients undergoing ureteroscopy without histories that would limit use of opioids, gabapentinoids, and nonsteroidal medications were enrolled. Either 300 mg pregabalin or placebo was administered 1 hour before ureteroscopy. Pain was assessed using a visual analogue scale before administration and 1 hour after surgery. Clinical factors, pain scores, a proxy for cognition, patient satisfaction, and opioid prescribing were assessed in the first 30 postoperative days. RESULTS: A total of 118 patients were enrolled over a 2-year period. Patients who received pregabalin were younger than those who received placebo (median of 44 years vs 57). Postoperative pain scores were higher in those who received pregabalin (3.7 vs 2.0, P = .004), a finding that remained statistically significant when accounting for patient age and preoperative pain scores. There was no difference in the measure of cognition or in reports of adverse events. CONCLUSIONS: In this trial evaluating the efficacy of single-dose perioperative pregabalin in ureteroscopy, pregabalin did not decrease postoperative pain when compared to placebo. Urologists should not routinely use this adjunctive medication in ureteroscopy, as it is unlikely to provide benefit.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Rosen GH, Hargis PA, Kahveci A, et al. Randomized Controlled Trial of Single-dose Perioperative Pregabalin in Ureteroscopy. J Urol. 2023. PMID: 37307424. doi:10.1097/JU.0000000000003572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。